Literature DB >> 2206883

The expression of blood group P1 in post-enteropathic haemolytic uraemic syndrome.

C M Taylor1, D V Milford, P E Rose, T C Roy, B Rowe.   

Abstract

Blood group P1 expression was scored by direct agglutination in 32 patients who had previously developed post-enteropathic haemolytic uraemic syndrome (HUS). Sixty-six children of similar ages undergoing venepuncture for other renal disorders acted as controls. The expression of P1 in controls was that expected from the normal caucasian population, 23% being negative. By contrast, there was an excess of HUS patients with weak or absent expression of P1 (chi 2 for linear trend 5.45, P less than 0.02), and this was particularly evident in those with a poor outcome. Verotoxin (VT), which is associated with HUS, requires the terminal disaccharide of the P1 antigen to bind to cells, and after internalization disrupts the transcription of ribonucleic acid. Mature erythrocytes do not synthesize protein and may be toxin resistant. We postulate that strong expression of P1 antigen may promote the binding of VT to red cells and thus reduce the dose to vulnerable nucleated endothelial cells. P1 positivity may be protective, and P1 negativity a risk factor in HUS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2206883     DOI: 10.1007/bf00858441

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  9 in total

1.  BIOCHEMISTRY OF ORGAN GLYCOLIPIDS. III. THE STRUCTURES OF HUMAN KIDNEY CEREBROSIDE SULFURIC ESTER, CERAMIDE DIHEXOSIDE AND CERAMIDE TRIHEXOSIDE.

Authors:  A MAKITA; T YAMAKAWA
Journal:  J Biochem       Date:  1964-04       Impact factor: 3.387

2.  Location of adhesion sites for P-fimbriated and for 075X-positive Escherichia coli in the human kidney.

Authors:  B Nowicki; H Holthöfer; T Saraneva; M Rhen; V Väisänen-Rhen; T K Korhonen
Journal:  Microb Pathog       Date:  1986-04       Impact factor: 3.738

3.  Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1.

Authors:  A A Lindberg; J E Brown; N Strömberg; M Westling-Ryd; J E Schultz; K A Karlsson
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

4.  Vero cytotoxin-producing strains of Escherichia coli from children with haemolytic uraemic syndrome and their detection by specific DNA probes.

Authors:  S M Scotland; B Rowe; H R Smith; G A Willshaw; R J Gross
Journal:  J Med Microbiol       Date:  1988-04       Impact factor: 2.472

5.  Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

Authors:  M A Karmali; B T Steele; M Petric; C Lim
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

6.  Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin.

Authors:  A O O'Brien; T A Lively; M E Chen; S W Rothman; S B Formal
Journal:  Lancet       Date:  1983-03-26       Impact factor: 79.321

7.  Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.

Authors:  C A Lingwood; H Law; S Richardson; M Petric; J L Brunton; S De Grandis; M Karmali
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

8.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

9.  Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies.

Authors:  A Donohue-Rolfe; G T Keusch; C Edson; D Thorley-Lawson; M Jacewicz
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

  9 in total
  12 in total

1.  Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood.

Authors:  P C Rowe
Journal:  Can J Infect Dis       Date:  1995-03

Review 2.  New insights into the haemolytic uraemic syndromes.

Authors:  D V Milford; C M Taylor
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

Review 3.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

4.  Haemolytic anaemia after childhood Escherichia coli O 157 .H7 infection: are females at increased risk?

Authors:  P C Rowe; W Walop; H Lior; A M Mackenzie
Journal:  Epidemiol Infect       Date:  1991-06       Impact factor: 2.451

5.  Racial incidence of hemolytic-uremic syndrome.

Authors:  K J Sheth; J C Gill; P L Havens; H E Leichter
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

6.  Differing outcomes of Escherichia coli O157 colitis in identical twins.

Authors:  C D Inward; D V Milford; C M Taylor
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

7.  Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro.

Authors:  M Bitzan; S Richardson; C Huang; B Boyd; M Petric; M A Karmali
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Binding of shiga toxin 2e to porcine erythrocytes in vivo and in vitro.

Authors:  Ilze Matise; Nancy A Cornick; James E Samuel; Harley W Moon
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  P1 blood group antigen expression and epidemic hemolytic uremic syndrome.

Authors:  P H Orr; V Dong; M L Schroeder; M R Ogborn
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

Review 10.  Racial incidence of hemolytic uremic syndrome.

Authors:  S M Jernigan; F B Waldo
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.